IP Library › Granted Patent US 10,898,459
Granted Patent B2
US 10,898,459 · App. 15/814,767 · Granted Jan 26, 2021

Method of treating chronic kidney disease

Inventors: Keith Chan (Rockville, MD); Winston Town (Hong Kong, CN)
Assignee: Panion & BF Biotech Inc.
A61K31/295A61K9/143A61K31/555A61K33/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,898,459
App. No.
15/814,767
Granted
Jan 26, 2021
Kind
B2
Abstract

The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.

Claims (14)

1. A method of treating chronic kidney disease, comprising administering a therapeutically effective amount of ferric citrate to a subject in need thereof.

2. The method of claim 1 , wherein the ferric citrate has a BET active surface area selected from at least 16 m2/g and 16 m2/g to 20 m2/g.

3. The method of claim 1 , wherein the ferric citrate has an intrinsic dissolution rate selected from at least 2 mg/cm2/min and 2 to 4 mg/cm2/min.

4. The method of claim 1 , wherein the subject is a human.

5. The method of claim 1 , wherein the clinical stage of chronic kidney disease is selected from stage 1, stage 2, stage 3, stage 4, and stage 5 (end stage renal disease).

6. The method of claim 1 , wherein the subject is undergoing dialysis.

7. The method of claim 1 , wherein the ferric citrate is administered at a dose of 2 g/day to 20 g/day.

8. The method of claim 1 , wherein the ferric citrate is administered orally.

9. The method of claim 8 , wherein the ferric citrate is formulated as a tablet, a powder, a capsule or a granule.

10. The method of claim 1 , wherein the ferric citrate is administered at a dose of 1 g/day to 15 g/day.

11. The method of claim 1 , wherein the ferric citrate is administered at a dose of 2 g/day, 4 g/day, 6 g/day, or 8 g/day.

12. The method of claim 1 , wherein the ferric citrate is administered at a dose of 3 g/day.

13. The method of claim 1 , wherein the ferric citrate is administered at a dose of 6 g/day.

14. The method of claim 8 , wherein the ferric citrate is formulated as a tablet.

Assignments (17)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jun 25, 2024
From: BIOPHARMA CREDIT PLC
To: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
Reel/Frame 067839/0134 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 29, 2024
From: BIOPHARMA CREDIT PLC
To: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
Reel/Frame 066377/0741 →
FIFTEENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 4, 2024
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 066205/0143 →
THIRTEENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 29, 2023
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 063189/0065 →
TWELFTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 29, 2022
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 062012/0561 →
ELEVENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 22, 2022
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 061297/0238 →
TENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 16, 2022
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 060529/0168 →
SECURITY INTEREST Recorded Dec 15, 2021
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 058399/0055 →
SEVENTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Sep 12, 2021
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 057474/0770 →
SIXTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 11, 2021
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 056544/0468 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2021
From: CHAN, KEITH; TOWN, WINSTON; GLOBOASIA, LLC
To: PANION & BF BIOTECH INC.
Reel/Frame 056172/0860 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2021
From: CHAN, KEITH; TOWN, WINSTON
To: GLOBOASIA, LLC
Reel/Frame 056172/0873 →
FIFTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 30, 2021
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 055776/0491 →
FOURTH AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 17, 2020
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 054793/0455 →
THIRD AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Sep 10, 2020
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 054173/0451 →
SECOND AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Sep 2, 2020
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 053671/0221 →
SECURITY INTEREST Recorded Apr 2, 2020
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 052295/0662 →
Priority Claims (1)
WO PCT/US2006/032385 · Aug 18, 2006 · international
Continuity (3)
Continuation 12162543
Provisional Application 60763253 · Jan 30, 2006
Related Publication 20180133191A1 · May 17, 2018